SCHEMBL376702

SCHEMBL376702

CO[C@H]1CCN(C(=O)OCc2ccccc2)C[C@@H]1Nc1ccnc(-c2cnc3ccccn23)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 2/20 0.44
CDK2 P24941 3/20 0.43
MAPK8 P45983 3/20 0.43
MAPK9 P45984 3/20 0.43
MAPK10 P53779 2/20 0.43
JUN P05412 2/20 0.43
GRIN2B Q13224 6/20 0.40
CYP2D6 P10635 4/20 0.40
CYP2C9 P11712 4/20 0.40
CYP3A4 P08684 3/20 0.40
IRAK4 Q9NWZ3 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
IGF1R P08069 2/20 0.38
ROCK2 O75116 1/20 0.38
USP30 Q70CQ3 1/20 0.38
IDH1 O75874 1/20 0.38
LCK P06239 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3234316 0.89 CDK2 (0.46) KITCDK2MAPK8MAPK9MAPK10
SCHEMBL376436 0.80 MAPK8 (0.42) CDK2MAPK8MAPK9MAPK10JUN
SCHEMBL376703 0.78 KIT (0.45) KITCDK2MAPK8MAPK9MAPK10
SCHEMBL376538 0.76 GRIN2B (0.44) CDK2MAPK8MAPK9MAPK10JUN
SCHEMBL377087 0.76 GRIN2B (0.44) CDK2MAPK8MAPK9MAPK10JUN
SCHEMBL12553163 0.76 IRAK4 (0.53) KITCDK2MAPK8MAPK9MAPK10
SCHEMBL376437 0.70 MAPK8 (0.43) CDK2MAPK8MAPK9MAPK10JUN
SCHEMBL3238386 0.69 CDK2 (0.46) CDK2MAPK8MAPK9MAPK10JUN
SCHEMBL29642337 0.69 SMN1; SMN2 (0.52) GRIN2BCYP2D6CYP2C9CYP3A4NPC1
SCHEMBL19015604 0.69 SMN1; SMN2 (0.57) GRIN2BCYP2D6CYP2C9NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2328890-B1 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER (US) 2012-01-25 EP disclosed
EP-2328890-B1 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER (US) 2012-01-25 EP disclosed
US-20110144084-A1 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER INC (US) 2011-06-16 US disclosed
US-20110144084-A1 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER INC (US) 2011-06-16 US disclosed
US-20110144084-A1 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER INC (US) 2011-06-16 US disclosed
EP-2328890-A1 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS Pfizer Inc. (US) 2011-06-08 EP disclosed
WO-2010016005-A1 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER INC. (US) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144084-A1 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS CHKA, CSNK1A1, CHKB KIT 324/4885CDK2 157/4885MAPK8 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.